Enter your login e-mail to the account
Search
- Systemic lupus erythematosus – an overview of new knowledge in pathogenesis, clinical picture and treatment
doc. Ing. Stanislava Blažíčková, PhD., prof. MUDr. Jozef Rovenský, DrSc., FRPC, MUDr. Ivana Stiborová
(2/2012, Review articles )
- New drugs era in treating multiple sclerosis
MUDr. Marta Vachová
(5/2009, Review articles ) - Ocrelizumab – clinical evaluation and disease progression – 6,5 years data
MUDr. Eva Recmanová
(5/2021, Review articles ) - The initial results and our experiences from the OCARINA II study indicate that the subcutaneous form of ocrelizumab is comparable in efficacy to the intravenous form
MUDr. Michal Dufek, Ph.D.
(5/2024, Case reports ) - Safety monitoring of escalation treatment of multiple sclerosis
MUDr. Jiří Piťha
(5/2019, Review articles ) - Experience with shortened ocrelizumab infusion – ENSEMBLE PLUS study
doc. MUDr. Yvonne Benešová, Ph.D.
(1/2022, Review articles ) - Anti CD20 multiple sclerosis therapy
Doc. MUDr. Pavel Štourač, Ph.D.
(1/2018, Pharmacotherapy ) - Early highefficacy mulitple sclerosis treatment: therapeutic success despite safety barriers
MUDr. Dominika Šťastná, Ph.D., prof. MUDr. Manuela Vaněčková, Ph.D., doc. MUDr. Dana Horáková, Ph.D.
(6/2023, Case reports ) - Efficacy and safety of ocrelizumab in multiple sclerosis
MUDr. Radek Ampapa
(5/2017, Review articles ) - Long term efficacy of ocrelizumab on MRI parameters in multiple sclerosis patients
MUDr. Pavel Hradílek, Ph.D.
(1/2020, Review articles ) - The use of monoclonal antibodies in neurology
prof. MUDr. Egon Kurča, PhD., MUDr. Mária Cuninková
(6/2011, Main topic ) - Ocrelizumab since the first multiple sclerosis attack – a milestone in reimbursement criteria
MUDr. Dominika Šťastná, MUDr. Ingrid Menkyová, doc. MUDr. Dana Horáková, Ph.D.
(4/2022, Review articles ) - Immunological outlook on modern therapy of multiple sclerosis
doc. MUDr. Vojtěch Thon, Ph.D.
(5/2016, From the boundary of neurology ) - Improved cognitive function and employment in patients with relapsing multiple sclerosis treated with ocrelizumab
MUDr. Marek Peterka
(4/2023, Review articles ) - Safety aspects of treating relapsing-remitting multiple sclerosis
MUDr. Radek Ampapa, MUDr. Stanislav Kopecký
(5/2016, Review articles ) - Adherence to treatment in multiple sclerosis: case reports of three female patients on high-efficacy therapy with ocrelizumab
MUDr. Jana Pavlíčková, Ph.D.
(3/2024, Case reports ) - The role of B lymphocytes in the immunopathogenesis and treatment of multiple sclerosis
prof. MUDr. Ľubomír Lisý, DrSc.
(3/2024, Informations ) - Ocrelizumab – pharmacoloical profile
doc. MUDr. Radomír Taláb, CSc., MUDr. Marika Talábová
(5/2018, Pharmacotherapy ) - NEDA-4 concept as a treatment outcome in multiple sclerosis patients
MUDr. Pavel Hradílek, Ph.D.
(3/2016, Review articles ) - Monoklonální protilátky v léčbě roztroušené sklerózy
MUDr. Marek Peterka , MUDr. Zdeněk Kasl, Ph.D.
(2/2018, Pharmacotherapy ) - Biological therapy by Ocrelizumab (antiCD20) is surprisingly clinically effective in multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2017, From the boundary of neurology ) - Long-term data of multiple sclerosis treatment with ocrelizumab – eficacy, safety and clinical experience
MUDr. Mgr. Matouš Rous, MUDr. Zuzana Rous, Ph.D.
(6/2021, Review articles ) - Treatment of multiple sclerosis in Czech Republic – options and reality
MUDr. Michal Dufek
(1/2014, Review articles ) - Ocrelizumab – what we know, what we can improve now, what we can improve in the future
MUDr. Martin Elišák, Ph.D.
(1/2024, Review articles ) - Treatment persistence to ocrelizumab and local experience
MUDr. Simona Halúsková, prof. MUDr. Martin Vališ, Ph.D., FEAN
(3/2021, Review articles ) - Ocrelizumab is dampening the harm inflammation in patients with multiple sclerosis with little impact on protective immunity
prof. RNDr. Jan Krejsek, CSc.
(3/2020, From the boundary of neurology ) - B lymfocyty v roztroušené skleróze mozkomíšní a postavení biologika cílícího na B lymfocyty v její léčbě
prof. RNDr. Jan Krejsek, CSc.
(3/2018, From the boundary of neurology ) - Ocrelizumab – long-term efficacy and safety in real-world clinical practice in patients with relapsingremitting multiple sclerosis
MUDr. Martin Elišák, Ph.D.
(3/2022, Review articles ) - New perspective treatment of multiple sclerosis
doc. MUDr. Vladimír Donáth, CSc., MUDr. Silvia Laurincová
(2/2014, Main topic ) - Ocrelizumab, clinical aktivity and progression – long-term data
MUDr. Zbyšek Pavelek, PhD., doc. MUDr. Martin Vališ, Ph.D.
(3/2019, Pharmacotherapy ) - Longterm safety of Ocrelizumab in Multiple Sclerosis treatment
MUDr. Marek Peterka , MUDr. Pavel Potužník
(4/2020, Review articles ) - Biologics targeting CD20 molecule on B cells in the therapy of multiple sclerosis patients
Prof. RNDr. Jan Krejsek, CSc.
(6/2022, From the boundary of neurology ) - Shorter infusion of ocrelizumab in the treatment of multiple sclerosis
MUDr. Marek Peterka , MUDr. Pavel Potužník
(4/2021, Review articles ) - MR monitoring of activity of multiple sclerosis patients: conventional techniques and long-term MR monitoring of ocrelizumab therapy
prof. MUDr. Manuela Vaněčková, Ph.D.
(6/2019, From the boundary of neurology ) - Ocrelizumab v léčbě roztroušené sklerózy
Prof. MUDr. Eva Kubala Havrdová, CSc.
(4/2017, Pharmacotherapy ) - B‑ lymphocyte‑ targeted MS therapy: from theory to a decade of ocrelizumab in practice
MUDr. Dominika Šťastná, Ph.D., MUDr. Jana Seňavová, prof. MUDr. Dana Horáková, Ph.D.
(2/2024, Review articles ) - Does the development of new drugs for multiple sclerosis change the prognosis of the patient?
prof. MUDr. Eva Havrdová, CSc.
(3/2011, Review articles ) - Ocrelizumab and novel therapeutic goals in multiple sclerosis
MUDr. Radek Ampapa
(2/2020, Review articles )
- New therapy options for multiple sclerosis
Mgr. Ivana Pankuchová, MUDr. Ľubica Procházková, CSc., PharmDr. Adela Čorejová, PhD.
(4/2013, Current pharmacotherapy )